In a scathing report, a pair of non-governmental organizations accused the European pharmaceutical industry of “failing to meaningfully invest” resources in the Innovative Medicines Initiative — a widely touted public-private partnership — in areas where research is badly needed.
Instead, the industry steered so-called in-kind contributions — such as personnel and facilities — to projects that were more commercially profitable, rather than those focused on long-term preparedness for epidemics, neglected tropical diseases, and HIV/AIDS, among other issues. And the NGOs also argued that the IMI was “late” in addressing the spread of the Ebola virus.
About the Author Reprints
